Resverlogix Corp. (TSE:RVX – Get Free Report) shares reached a new 52-week low on Tuesday . The company traded as low as C$0.06 and last traded at C$0.06, with a volume of 5250 shares. The stock had previously closed at C$0.06.
Resverlogix Stock Performance
The stock has a 50 day moving average price of C$0.06 and a two-hundred day moving average price of C$0.07. The company has a market capitalization of C$14.97 million, a PE ratio of -1.10 and a beta of 0.78.
Resverlogix Company Profile
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases.
Featured Stories
- Five stocks we like better than Resverlogix
- How to invest in blue chip stocks
- 3 Value Stocks Too Small For Buffett’s Portfolio
- Want to Profit on the Downtrend? Downtrends, Explained.
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- The How And Why of Investing in Oil Stocks
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
